Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:13:28.012Z.
Consensus retrieved: 2026-10-06T15:56:46.207Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:13:28.012Z.
Quote observation: 2026-10-06T19:09:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 79d0a2820bd4cbdc8dee1371cb6304dc007cf4c401fb8f8a9623f82368031b99
Forward PE Ratio (N/A) = Dated Quote Price ($1.75) / Consensus Forward EPS ($-8.96)
FORWARD PE RATIO
N/A
TransCode Therapeutics, Inc.
Market Cap
$1.85M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| TransCode Therapeutics, Inc. (RNAZ) | $1.85M | N/A |
| Tenon Medical, Inc. (TNON)vs › | $1.85M | N/A |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.79M | N/A |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.87M | N/A |
| Autonomix Medical, Inc. (AMIX)vs › | $1.91M | N/A |
| Beyond Air, Inc. (XAIR)vs › | $1.93M | N/A |
| Silo Pharma, Inc. (SILO)vs › | $1.63M | N/A |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.51M | N/A |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.16M | N/A |
| Curis, Inc. (CRIS)vs › | $1.48M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.75, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-8.96 | $-8.96 – $-8.96 | 1 | n/m |
| 2027-12-31 | $-6.72 | $-6.72 – $-6.72 | 1 | n/m |
| 2028-12-31 | $-5.60 | $-5.60 – $-5.60 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
